Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Cortes

Showing results (621-630 of 713) with videos related to

Pageof 72
Sort By:
Blood|October 13, 2007
Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatmentAndreas Hochhaus, Brian Druker, Charles Sawyers, et al.
The New England Journal of Medicine|June 8, 2010
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemiaHagop Kantarjian, Neil P Shah, Andreas Hochhaus, et al.
Haematologica|December 9, 2016
Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemiaJorge Cortes, Moshe Talpaz, Hedy P Smith, et al.
Cancer|February 28, 2019
Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemiaChristopher B Benton, Prajwal C Boddu, Courtney D DiNardo, et al.
Blood|January 20, 2017
Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman diseaseLi Yu, Meifeng Tu, Jorge Cortes, et al.
Cancer|April 16, 2019
Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysisElias J Jabbour, Koji Sasaki, Farhad Ravandi, et al.
British Journal of Haematology|November 23, 2017
The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximabPreetesh Jain, Graciela M Nogueras González, Rashmi Kanagal-Shamanna, et al.
American Journal of Hematology|July 31, 2016
Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapyNicholas J Short, Christopher B Benton, Hsiang-Chun Chen, et al.
Blood|May 23, 2008
Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemiaGuillermo Garcia-Manero, Sarit Assouline, Jorge Cortes, et al.
Leukemia|January 29, 2024
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trialsElias Jabbour, Jane Apperley, Jorge Cortes, et al.
Pageof 72

Showing results (621-630 of 713) with videos related to

Sort By:
Pageof 72
Blood|October 13, 2007
Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatmentAndreas Hochhaus, Brian Druker, Charles Sawyers, et al.
The New England Journal of Medicine|June 8, 2010
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemiaHagop Kantarjian, Neil P Shah, Andreas Hochhaus, et al.
Haematologica|December 9, 2016
Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemiaJorge Cortes, Moshe Talpaz, Hedy P Smith, et al.
Cancer|February 28, 2019
Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemiaChristopher B Benton, Prajwal C Boddu, Courtney D DiNardo, et al.
Blood|January 20, 2017
Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman diseaseLi Yu, Meifeng Tu, Jorge Cortes, et al.
Cancer|April 16, 2019
Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysisElias J Jabbour, Koji Sasaki, Farhad Ravandi, et al.
British Journal of Haematology|November 23, 2017
The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximabPreetesh Jain, Graciela M Nogueras González, Rashmi Kanagal-Shamanna, et al.
American Journal of Hematology|July 31, 2016
Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapyNicholas J Short, Christopher B Benton, Hsiang-Chun Chen, et al.
Blood|May 23, 2008
Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemiaGuillermo Garcia-Manero, Sarit Assouline, Jorge Cortes, et al.
Leukemia|January 29, 2024
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trialsElias Jabbour, Jane Apperley, Jorge Cortes, et al.
Pageof 72